Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
GPCR
GPCR
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
GPCR News
Casdin Capital Reduces Stake in Structure Therapeutics
Feb 27 2026
Fool
Structure Therapeutics Reports Q4 Net Income of $33 Million
Feb 26 2026
seekingalpha
BVF Increases Stake in Structure Therapeutics with $11.2 Million Purchase
Feb 25 2026
Fool
Eli Lilly's Dominance in Obesity Drug Market Reinforced
Feb 23 2026
CNBC
Rock Springs Capital Reduces Stake in Structure Therapeutics
Feb 17 2026
Fool
Structure Therapeutics' GLP-1 Drug Shows Promising Potential
Feb 05 2026
Fool
Structure Therapeutics Emerges as Potential Takeover Target for Big Pharma
Jan 30 2026
seekingalpha
Structure Therapeutics Advances Aleniglipron into Phase 3 Trials Following Novo Nordisk's Oral GLP-1 Launch
Jan 23 2026
Benzinga
Eli Lilly and Novo Nordisk Drive Diversification in Obesity Drug Market
Jan 23 2026
CNBC
Structure Therapeutics Advances Weight-Loss Pill with 11.3% Weight Loss in 36 Weeks
Jan 15 2026
Benzinga
Viking Therapeutics CEO Highlights Broad Strategic Interest in Weight-Loss Drug Deals, Shares Surge 17%
Jan 14 2026
stocktwits
FMR LLC Sells 52,356 Shares of Structure Therapeutics for Approximately $3.8 Million
Jan 13 2026
Fool
Structure Therapeutics (GPCR) Sells Over 50,000 Shares for Nearly $4 Million
Jan 13 2026
NASDAQ.COM
Moderna Inc (MRNA) Projects $1.9 Billion Revenue for 2025, Shares Surge 12.8%
Jan 13 2026
Benzinga
Anticipate a Hectic Year for Obesity Medications with New Pills Launching
Jan 12 2026
Barron's
Structure Therapeutics Reports Positive Phase 2 Data for Aleniglipron, Stock Soars
Jan 11 2026
NASDAQ.COM
Show More News
